JP2020518639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518639A5 JP2020518639A5 JP2019560384A JP2019560384A JP2020518639A5 JP 2020518639 A5 JP2020518639 A5 JP 2020518639A5 JP 2019560384 A JP2019560384 A JP 2019560384A JP 2019560384 A JP2019560384 A JP 2019560384A JP 2020518639 A5 JP2020518639 A5 JP 2020518639A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- target
- psma
- therapeutic agent
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 55
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 40
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 40
- 229940124597 therapeutic agent Drugs 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 230000008685 targeting Effects 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 26
- 239000012830 cancer therapeutic Substances 0.000 claims description 26
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims description 22
- 102000005962 receptors Human genes 0.000 claims description 22
- 108020003175 receptors Proteins 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- -1 chlorambusyl Chemical compound 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 208000002458 carcinoid tumor Diseases 0.000 claims description 9
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 6
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- 238000002648 combination therapy Methods 0.000 claims description 5
- OLWVRJUNLXQDSP-RYUDHWBXSA-N (2s)-2-[[(1s)-1-carboxy-5-[(6-fluoropyridine-3-carbonyl)amino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)C1=CC=C(F)N=C1 OLWVRJUNLXQDSP-RYUDHWBXSA-N 0.000 claims description 4
- JOOSAULNUZKCRN-UHFFFAOYSA-N OC(=O)CCC(C[PH2]=O)C(O)=O Chemical class OC(=O)CCC(C[PH2]=O)C(O)=O JOOSAULNUZKCRN-UHFFFAOYSA-N 0.000 claims description 4
- 108010037516 PSMA-617 Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- IDTMSHGCAZPVLC-RYUDHWBXSA-N n-({(1r)-1-carboxy-2-[(4-fluorobenzyl)sulfanyl]ethyl}carbamoyl)-l-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CSCC1=CC=C(F)C=C1 IDTMSHGCAZPVLC-RYUDHWBXSA-N 0.000 claims description 4
- 150000008298 phosphoramidates Chemical class 0.000 claims description 4
- 108091006082 receptor inhibitors Proteins 0.000 claims description 4
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 claims description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- 241000483002 Euproctis similis Species 0.000 claims description 3
- 206010018404 Glucagonoma Diseases 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 3
- 206010033963 Parathyroid tumour Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 102000001708 Protein Isoforms Human genes 0.000 claims description 3
- 108010029485 Protein Isoforms Proteins 0.000 claims description 3
- 108050001286 Somatostatin Receptor Proteins 0.000 claims description 3
- 102000011096 Somatostatin receptor Human genes 0.000 claims description 3
- 206010041329 Somatostatinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 201000010425 adrenal medulla cancer Diseases 0.000 claims description 3
- 208000024727 adrenal medulla neoplasm Diseases 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims description 3
- 229960005243 carmustine Drugs 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 238000011970 concomitant therapy Methods 0.000 claims description 3
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 3
- 229960005501 duocarmycin Drugs 0.000 claims description 3
- 229930184221 duocarmycin Natural products 0.000 claims description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
- 229960002074 flutamide Drugs 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 3
- 201000000052 gastrinoma Diseases 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 229960000908 idarubicin Drugs 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- 206010022498 insulinoma Diseases 0.000 claims description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 3
- 229960004338 leuprorelin Drugs 0.000 claims description 3
- 229960004961 mechlorethamine Drugs 0.000 claims description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004296 megestrol acetate Drugs 0.000 claims description 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 3
- 208000007312 paraganglioma Diseases 0.000 claims description 3
- 208000010916 pituitary tumor Diseases 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 201000000963 pulmonary neuroendocrine tumor Diseases 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 102000004052 somatostatin receptor 2 Human genes 0.000 claims description 3
- 108090000586 somatostatin receptor 2 Proteins 0.000 claims description 3
- 210000000115 thoracic cavity Anatomy 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims description 3
- 210000001635 urinary tract Anatomy 0.000 claims description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023182197A JP7701749B2 (ja) | 2017-05-02 | 2023-10-24 | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500187P | 2017-05-02 | 2017-05-02 | |
| US62/500,187 | 2017-05-02 | ||
| PCT/US2018/030620 WO2018204477A1 (en) | 2017-05-02 | 2018-05-02 | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023182197A Division JP7701749B2 (ja) | 2017-05-02 | 2023-10-24 | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518639A JP2020518639A (ja) | 2020-06-25 |
| JP2020518639A5 true JP2020518639A5 (https=) | 2021-05-13 |
| JP7373998B2 JP7373998B2 (ja) | 2023-11-06 |
Family
ID=64016565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560384A Active JP7373998B2 (ja) | 2017-05-02 | 2018-05-02 | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| JP2023182197A Active JP7701749B2 (ja) | 2017-05-02 | 2023-10-24 | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023182197A Active JP7701749B2 (ja) | 2017-05-02 | 2023-10-24 | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US11491247B2 (https=) |
| EP (1) | EP3618867A4 (https=) |
| JP (2) | JP7373998B2 (https=) |
| WO (1) | WO2018204477A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| JP2023547998A (ja) * | 2020-10-01 | 2023-11-15 | コーネル ユニバーシティー | 低分子リガンドの取り込み、内在化、及び／または保持を増加させるための方法及び組成物 |
| US20240000979A1 (en) * | 2020-10-01 | 2024-01-04 | Cornell University | Methods and compositions for synergistic uptake and retention of small molecule ligands |
| CN113354709B (zh) * | 2021-06-03 | 2023-06-09 | 江苏华益科技有限公司 | 一种转移性前列腺癌靶向性药物前体的固相合成方法 |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| KR20250171285A (ko) * | 2023-04-12 | 2025-12-08 | 코넬 유니버시티 | 암 치료용 방사선치료 접합체 |
| WO2025029946A1 (en) | 2023-07-31 | 2025-02-06 | Curium Us Llc | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| US7736651B1 (en) | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
| EP1173192B1 (en) | 1999-03-08 | 2018-08-15 | Gerhart Graupner | Methods and compositions for targeted drug delivery |
| CA2391534A1 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| US6683162B2 (en) | 2000-09-15 | 2004-01-27 | Sloan Kettering Institute Of Cancer Research | Targeted alpha particle therapy using actinium-255 conjugates |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| EP1427377A4 (en) | 2001-09-20 | 2006-04-12 | Cornell Res Foundation Inc | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| WO2005070456A2 (en) | 2004-01-09 | 2005-08-04 | Millennium Pharmaceuticals, Inc. | Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies |
| WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| NO20220050A1 (no) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| EP2132133A4 (en) | 2007-03-02 | 2013-04-17 | Univ Illinois | RELEASE OF PARTICULATE ACTIVE SUBSTANCES |
| ES2700234T3 (es) | 2007-06-26 | 2019-02-14 | Univ Johns Hopkins | Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes |
| PT2318366T (pt) | 2008-08-01 | 2017-08-02 | Univ Johns Hopkins | Agentes de ligação a psma e suas utilizações |
| US8889631B2 (en) | 2008-08-18 | 2014-11-18 | The University Of Kansas | Disruptors of early/recycling endosomes |
| US9056841B2 (en) | 2009-03-19 | 2015-06-16 | The Johns Hopkins University | PSMA-targeting compounds and uses thereof |
| US10717750B2 (en) | 2009-03-19 | 2020-07-21 | The Johns Hopkins University | 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents |
| JP2013504585A (ja) | 2009-09-09 | 2013-02-07 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| WO2011108955A1 (en) | 2010-03-03 | 2011-09-09 | Universidade De Coimbra | Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s) |
| CA2841120C (en) | 2011-07-11 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-ir700 conjugates for photodynamic therapy |
| AU2012294639B2 (en) | 2011-08-05 | 2017-10-26 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| EP2800586A1 (en) | 2012-01-03 | 2014-11-12 | Invictus Oncology Pvt. Ltd. | Ligand-targeted molecules and methods thereof |
| CA2869748C (en) | 2012-04-12 | 2017-10-24 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
| WO2014001326A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
| US8990921B2 (en) | 2013-02-21 | 2015-03-24 | Atheer, Inc. | Apparatus for processing with a secure system manager |
| JP6239246B2 (ja) * | 2013-03-13 | 2017-11-29 | 株式会社日立ハイテクノロジーズ | 荷電粒子線装置、試料観察方法、試料台、観察システム、および発光部材 |
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| US9636419B2 (en) | 2013-10-11 | 2017-05-02 | The Universit of Kansas | Targeting multiple receptors on a cell surface for specific cell targeting |
| EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| US20150110814A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| EP3129065A4 (en) | 2014-03-12 | 2018-01-24 | Invictus Oncology Pvt. Ltd. | Targeted drug delivery through affinity based linkers |
| CN106660943B (zh) | 2014-05-06 | 2020-03-17 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
| EP3200823B1 (en) | 2014-10-02 | 2022-11-23 | City of Hope | Multivalent meditopes, meditope-binding antibodies and uses thereof |
| EP3209336B1 (en) | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2016123593A1 (en) | 2015-01-30 | 2016-08-04 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| RS65188B1 (sr) | 2016-03-22 | 2024-03-29 | Univ Johns Hopkins | Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate |
| CN109843339B (zh) | 2016-06-23 | 2023-07-07 | 康奈尔大学 | 影响肿瘤杀伤的双重靶向构建体 |
| GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| WO2018108287A1 (en) | 2016-12-15 | 2018-06-21 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of pmsa expressing cancers |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| US20200339625A1 (en) | 2017-10-22 | 2020-10-29 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| SG11202106603UA (en) | 2018-12-21 | 2021-07-29 | Sapreme Tech Bv | Biologically active cluster of molecules |
| US11478493B2 (en) | 2019-03-08 | 2022-10-25 | University Of South Carolina | Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers |
| US20220081401A1 (en) | 2019-05-29 | 2022-03-17 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| JP2023547998A (ja) | 2020-10-01 | 2023-11-15 | コーネル ユニバーシティー | 低分子リガンドの取り込み、内在化、及び／または保持を増加させるための方法及び組成物 |
| US20240000979A1 (en) | 2020-10-01 | 2024-01-04 | Cornell University | Methods and compositions for synergistic uptake and retention of small molecule ligands |
-
2018
- 2018-05-02 WO PCT/US2018/030620 patent/WO2018204477A1/en not_active Ceased
- 2018-05-02 US US16/610,816 patent/US11491247B2/en active Active
- 2018-05-02 JP JP2019560384A patent/JP7373998B2/ja active Active
- 2018-05-02 EP EP18794018.4A patent/EP3618867A4/en active Pending
-
2021
- 2021-03-11 US US17/198,574 patent/US11738101B2/en active Active
-
2023
- 2023-08-01 US US18/363,369 patent/US12285503B2/en active Active
- 2023-10-24 JP JP2023182197A patent/JP7701749B2/ja active Active
-
2025
- 2025-03-25 US US19/089,896 patent/US20250249132A1/en not_active Abandoned
- 2025-11-21 US US19/396,767 patent/US20260083867A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518639A5 (https=) | ||
| Arnaldez et al. | Targeting the insulin growth factor receptor 1 | |
| JP7701749B2 (ja) | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 | |
| EP2784082A1 (en) | Disease site-delivering pharmaceutical compositions comprising paclitaxel. | |
| JP2023547999A5 (https=) | ||
| JP2022078296A (ja) | 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子 | |
| Petrioli et al. | Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience | |
| Ghiringhelli et al. | Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study | |
| Vorobiof et al. | First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: a multicentre phase II study | |
| EP4168008B1 (en) | A combination of belzutifan and lenvatinib for use in treating cancer | |
| Jeswani et al. | Advances in the delivery of cancer therapeutics: a comprehensive review | |
| CN120303009A (zh) | 治疗前列腺癌的方法 | |
| Shimizu et al. | Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors | |
| Gao et al. | Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles | |
| JP2023547998A5 (https=) | ||
| Shim et al. | Liposomal Co-Delivery of Omacetaxine Mepesuccinate and Doxorubicin for Synergistic Potentiation of Antitumor Activity: Shim et al. | |
| KR20110073486A (ko) | 신장 세포 암종 치료용 3,3',4,4'-테트라하이드록시-2,2'-바이피리딘-ｎ,ｎ'-디옥시드 | |
| Higano et al. | Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors | |
| Takano et al. | Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth | |
| Frampton et al. | Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma | |
| Kim et al. | Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer | |
| EP4591864A1 (en) | Pharmaceutical composition for destruction of tumor blood vessels | |
| EP4719377A1 (en) | Methods of using alternating electric fields and checkpoint inhibitors | |
| Zhu et al. | Current progresses of functional nanomaterials for imaging diagnosis and treatment of melanoma | |
| CN102427800A (zh) | 将活性剂优先分配到损伤部位的组合物和方法 |